Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.59 |
| ▸ | PDE5A | O76074 | 18/20 | 0.59 |
| ▸ | PDE6C | P51160 | 4/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.59 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.59 |
| ▸ | PDE2A | O00408 | 2/20 | 0.59 |
| ▸ | PDE9A | O76083 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 2/20 | 0.59 |
| ▸ | PDE1A | P54750 | 2/20 | 0.59 |
| ▸ | PDE11A | Q9HCR9 | 2/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.59 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.59 |
| ▸ | PDE6D | O43924 | 1/20 | 0.59 |
| ▸ | PDE8A | O60658 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | PDE6A | P16499 | 1/20 | 0.59 |
| ▸ | PDE6G | P18545 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL28695299 | 0.99 | PDE5A (0.59) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL20561619 | 0.95 | PDE5A (0.61) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28412134 | 0.89 | PDE5A (0.60) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28409225 | 0.88 | PDE5A (0.61) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL21401289 | 0.84 | PDE5A (0.49) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28485561 | 0.84 | PDE5A (0.49) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28890961 | 0.84 | KMT2A (0.71) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28409118 | 0.84 | PDE5A (0.58) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL28417263 | 0.84 | PDE5A (0.58) | PDE5APDE6CPDE3BPDE3AABCC4 | |
| SCHEMBL6716511 | 0.83 | PDE5A (0.84) | PDE5APDE6CPDE3BPDE3AABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553060-B1 | POLYCRYSTALLINE MESYLATE OF PHOSPHODIESTERASE TYPE 5 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JINAN MEILUWEI BIOTECHNOLOGY CO LTD (CN) | 2020-12-23 | — | — | EP | disclosed |
| US-10654859-B2 | Methanesulfonate polymorph of 5-type phosphodiesterase inhibitor and preparation method and applications thereof | Jinan Meiluwei Biotechnology Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| EP-3553060-A1 | POLYCRYSTALLINE MESYLATE OF PHOSPHODIESTERASE TYPE 5 INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Jinan Meiluwei Biotechnology Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190292192-A1 | METHANESULFONATE POLYMORPH OF 5-TYPE PHOSPHODIESTERASE INHIBITOR AND PREPARATION METHOD AND APPLICATIONS THEREOF | WANG, Jinglin (CN) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292192-A1 | METHANESULFONATE POLYMORPH OF 5-TYPE PHOSPHODIESTERASE INHIBITOR AND PREPARATION METHOD AND APPLICATIONS THEREOF | PDE5A, PDE3A, PDE9A | HTR1A 473/4885ADRA1A 165/4885PDE5A 1/4885 |
| US-10654859-B2 | Methanesulfonate polymorph of 5-type phosphodiesterase inhibitor and preparation method and applications thereof | PDE5A, PDE3A, PDE9A | HTR1A 473/4885ADRA1A 165/4885PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.